Inventiva
Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.
IVA | PA
Overview
Corporate Details
- ISIN(s):
- FR0013233012 (+2 more)
- LEI:
- 969500I9Y690B3FZW590
- Country:
- France
- Address:
- 50 RUE DE DIJON, 21121 DAIX
- Website:
- https://inventivapharma.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 00:00 |
Interim Report
RFS
|
French | 927.7 KB | ||
| 2025-08-25 09:57 |
Major Shareholding Notification
Franchissement de seuil
|
French | 114.0 KB | ||
| 2025-08-25 09:56 |
Major Shareholding Notification
Franchissement de seuil
|
French | 112.0 KB | ||
| 2025-08-19 15:35 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.8 KB | ||
| 2025-08-19 15:32 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.7 KB | ||
| 2025-08-19 15:19 |
Major Shareholding Notification
Franchissement de seuil
|
French | 116.1 KB | ||
| 2025-08-12 15:57 |
Major Shareholding Notification
Franchissement de seuil
|
French | 113.9 KB | ||
| 2025-08-12 15:52 |
Major Shareholding Notification
Franchissements de seuil
|
French | 121.6 KB | ||
| 2025-08-11 15:14 |
Major Shareholding Notification
Franchissement de seuil
|
French | 121.9 KB | ||
| 2025-06-17 17:02 |
Major Shareholding Notification
Franchissement de seuils
|
French | 113.4 KB | ||
| 2025-06-10 22:00 |
Board/Management Information
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Di…
|
English | 243.0 KB | ||
| 2025-05-27 22:00 |
Regulatory News Service
Inventiva Participera à la « Jefferies Global Healthcare Conference » et à la «…
|
French | 217.7 KB | ||
| 2025-05-27 22:00 |
Regulatory News Service
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference…
|
English | 160.0 KB | ||
| 2025-05-23 08:30 |
Earnings Release
Inventiva reports 2025 First Quarter Financial Information¹
|
English | 299.4 KB | ||
| 2025-05-23 08:30 |
Earnings Release
Inventiva publie ses informations financières¹ du 1er trimestre 2025
|
French | 335.4 KB |
Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Inventiva via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-05 | N/A | Other | Buy | 10,000 | N/A |
| 2023-12-08 | N/A | Other | Buy | 15,000 | N/A |
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
